RCS - N4 Pharma PLC - Grant Award for Professor Chengzhong Yu

N4 PharmaAnnouncement

27/06/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230627:nRSa9375Da&default-theme=true

RNS Number : 9375D  N4 Pharma PLC  27 June 2023

Reach - Non-Regulatory

 

27 June 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Grant Award for Professor Chengzhong Yu

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce it will be supporting the University of Queensland as part
of a recent grant award by the Australian Research Council.

 

The University of Queensland has announced that Professor Chengzhong Yu,
Senior Group Leader, Australian Institute for Bioengineering and
Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved
nanoparticle delivery system that enhances the performance of messenger
ribonucleic acid (mRNA) therapies. The new nanoparticle will be based on the
Company's patented nuvec® nanoparticle that it has licensed exclusively from
the University of Queensland.

N4 Pharma will work with Professor Yu to tackle the current challenges in
manufacturing mRNA therapeutics, by building new knowledge in custom-design of
functional nanomaterials for mRNA delivery. mRNA is a highly lucrative field
of therapeutic science and is emerging as a major drug platform.

A copy of the full announcement can be found here:
https://aibn.uq.edu.au/article/2023/06/linkage-grants-catapult-lab-ideas-production-line
(https://aibn.uq.edu.au/article/2023/06/linkage-grants-catapult-lab-ideas-production-line)

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are pleased to continue our close collaboration with Professor Yu and work
on new ways to build on the performance of our Nuvec® nanoparticle together."

 

 

 

Enquiries:

 N4 Pharma Plc                                          Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                         Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                  Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                   Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre-clinical and
clinical programs, N4 Pharma will seek to receive upfront payments, milestone
payments and ultimately royalty payments once products reach the market.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKABPNBKDBAB